Manufacturer with High Purity and Stable Quality
Chemical Name: N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine
Synonyms: ECPPA
CAS: 82717-96-2
Intermediate of Enalapril Maleate (CAS: 76095-16-4), an angiotensin converting enzyme (ACE) inhibitor, used to treat high blood pressure, diabetes kidney disease, and chronic heart failure.
High Quality, Commercial Production
| Chemical Name |
N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine |
| Synonyms |
ECPPA; Enalapril EP Impurity B |
| CAS Number |
82717-96-2 |
| CAT Number |
RF-PI246 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C15H21NO4 |
| Molecular Weight |
279.34 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White Powder |
| Specific Rotation |
+26.0° ~ +30.0° |
| Melting Point |
148.0~152.0℃ |
| Single Impurity |
≤0.50% |
| Total Impurities |
≤1.0% |
| Water Content |
≤0.50% |
| Purity |
≥99.0% (HPLC) |
| Test Standard |
Enterprise Standard |
| Usage |
Pharmaceutical Intermediate of Enalapril Maleate (CAS: 76095-16-4) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of ECPPA ; N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine (CAS: 82717-96-2) with high quality. ECPPA is an intermediate typically in the synthesis of Enalapril Maleate (CAS: 76095-16-4).
Enalapril Maleate (CAS: 76095-16-4) is an angiotensin converting enzyme inhibitor (ACE), used to treat high blood pressure, diabetes kidney disease, and chronic heart failure. An antihypertensive. Enalapril maleate is the second angiotensin converting enzyme inhibitor to reach the marketplace. Like captopril, the first entry in this area, enalapril is useful in the treatment of hypertension and congestive heart failure. It has a longer effective half-life than captopril, allowing once or twice-daily dosing, and appears to have a somewhat lower incidence of side effects.